VcR-CVAD induction chemotherapy followed by maintenance rituximab produces durable remissions in mantle cell lymphoma: a Wisconsin Oncology Network study

INTRODUCTION: VcR-CVAD was developed as an intermediate-intensity induction regimen with maintenance rituximab (MR) to improve remission durations after first-line therapy for mantle cell lymphoma (MCL) in older and younger MCL patients. PATIENTS AND METHODS: Patients with previously untreated MCL r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Lymphoma Myeloma Leuk
Main Authors: Chang, J.E., Carmichael, L.L., Kim, K., Peterson, C., Yang, D.T., Traynor, A.M., Werndli, J. E., Huie, M. S., McFarland, T. A., Volk, M., Blank, J., Callander, N.S., Longo, W.L., Kahl, B.S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5896779/
https://ncbi.nlm.nih.gov/pubmed/29191715
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2017.10.006
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados